Skip to main content
New Microbes and New Infections logoLink to New Microbes and New Infections
. 2022 Jul 1;48:101000. doi: 10.1016/j.nmni.2022.101000

Corrigendum to “Does ivermectin have a place in the treatment of mild Covid-19?” [New Microbes New Infect 46 (C) (2022 Mar) 100985]

Eli Schwartz 1
PMCID: PMC9247222  PMID: 35791412

The author regrets having incorrectly used in the Forest-Plot figure, under the column of “Total” the numbers which were the “non-events” numbers instead of the Total numbers. This is corrected now and has changed the Risk Ratio (95% CI) being now 0.77 (0.60-0.98) and P = 0.04.

These numbers were corrected in the figure and also in the last 2 lines of Table 1.

The corrected Figure and |Table are enclosed.

These changes did not affect any of the conclusions of the manuscript.

The authors would like to apologise for any inconvenience caused.

Fig. 1. Effect of ivermectin on prevention of hospitalization including studies with low concerns for bias. (Ref [3,7–9]).

Image 1

Table 1. Risk of hospitalization in non-hospitalized patients treated with ivermectin vs. molnupiravir

Drug (Ref) Ivermectin (3,7-9) Molnupiravir (10)
Total number of participants 2346
Drug- 1079/Placebo-1044
1408
Drug-709/Placebo-699
% High Risk Any co-morbidity = ∼75% All
% Positive in Placebo arm 129/1170 = 12.3% 68/699 = 9.7%
% Positive in active drug arm 98/1176 = 9.0% 48/709 = 6.8%
Risk ratio (95% CI) 0.77 (0.60-0.98) 0.69 (0.48 to 1.01)
P-value 0.04 0.04

Articles from New Microbes and New Infections are provided here courtesy of Elsevier

RESOURCES